Johnson & Johnson (JNJ) DIvidends Date & History

Key Takeaways

• Johnson & Johnson pays a quarterly dividend of $1.34 per share, equating to an annual payout of $5.36 and a yield of approximately 2.35%.
• The company boasts a 64-year streak of consecutive dividend increases, cementing its status as a Dividend King.
• Payout ratio stands at around 60%, indicating strong sustainability supported by robust free cash flow (FCF, cash generated after capital expenditures).
• Net debt is manageable at approximately $33 billion against $22 billion in cash, bolstering dividend reliability.
• Recent dividend hike of 3% to $1.34 per share announced in April 2026.
• Next ex-dividend date is May 26, 2026, with payment on June 9, 2026.

Dividend Overview

Johnson & Johnson (JNJ), a diversified healthcare giant spanning pharmaceuticals, medical devices, and consumer health products, maintains a shareholder-friendly dividend policy. The company currently offers a quarterly dividend of $1.34 per share, annualizing to $5.36, which provides a yield of about 2.35% based on recent share prices. Payments occur every three months, with the next ex-dividend date set for May 26, 2026. This positions JNJ as a classic dividend growth stock rather than a high-yield play, appealing to investors seeking reliable income paired with moderate appreciation potential in the stable healthcare sector.

Dividend History and Growth

Johnson & Johnson has an exemplary track record of dividend payments, with 64 consecutive years of increases as of 2026, including a recent 3% hike from $1.30 to $1.34 per share announced on April 14. Over the past five years, dividends have grown at an average annual rate of about 5%, reflecting consistent commitment even through economic cycles and sector challenges like patent cliffs. No cuts have occurred in over six decades, underscoring a long-term strategy prioritizing shareholder returns alongside innovation and acquisitions. Historical data from the company's investor relations confirms steady quarterly payouts since the 1960s.

Dividend Sustainability and Payout Ratio

The dividend's sustainability is robust, with a payout ratio of approximately 60%, meaning JNJ distributes about 60% of earnings as dividends, leaving ample room for reinvestment and growth. Trailing twelve-month levered FCF of $12.51 billion comfortably covers annual dividends exceeding $13 billion (based on shares outstanding). Earnings per share growth and operational cash flows provide strong coverage. Balance sheet strength includes $22 billion in cash against $55 billion in total debt, yielding net debt around $33 billion—low relative to $400+ billion market cap and EBITDA. This conservative leverage supports ongoing dividend hikes without strain.

Dividend Compared to Industry Peers

In the healthcare sector, JNJ's 2.35% yield is competitive but trails higher-yield peers like Pfizer (PFE) at around 6.8% and AbbVie (ABBV) near 3-4%, which prioritize income over growth. Merck (MRK) offers a similar profile with yields around 2-3%, while UnitedHealth (UNH) yields about 2.5%. JNJ stands out for its superior growth streak and lower payout ratio versus yield-chasing peers, making it average-to-attractive in a sector median of roughly 2.97%. Its diversified model enhances stability compared to pharma-focused rivals.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to streamline your research.

Is This Stock Attractive for Dividend Investors?

Johnson & Johnson appeals to conservative dividend growth investors prioritizing longevity and reliability over sky-high yields. Its 64-year streak suits long-term holders in retirement portfolios seeking healthcare exposure with inflation-beating payout growth averaging 5% annually. Income-focused investors may find the 2.35% yield modest compared to riskier high-yielders like PFE, but JNJ's pristine balance sheet, FCF coverage, and diversified revenue streams mitigate sector risks such as drug pricing pressures or litigation. For those balancing growth and income, it offers appeal amid stable demand for essentials like pharmaceuticals and devices. However, total returns depend on share price appreciation, which has lagged broader markets recently due to valuation concerns. Balanced investors may pair it with higher-yield peers for optimized portfolios.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations